Literature DB >> 6422325

Valproic acid-induced hyperammonemia in mentally retarded adults.

C A Williams, S Tiefenbach, J W McReynolds.   

Abstract

All individuals receiving valproic acid therapy in an institution for the mentally retarded were evaluated for hyperammonemia. Of these 19 adults, 6 had persistent and 5 others had intermittent hyperammonemia. The hyperammonemic patients were asymptomatic, except that 2 had occasional lethargy. Hyperammonemia was detected more often in younger adults and in those treated with multiple anticonvulsants, especially phenytoin. Valproate-induced hyperammonemia is probably the result of depletion of mitochondrial acetyl CoA and decreased production of N-acetylglutamate, the obligatory activator of the first enzyme of the urea cycle, carbamyl phosphate synthetase I. Anticonvulsant-mediated microsomal enzyme induction may also contribute.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6422325     DOI: 10.1212/wnl.34.4.550

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  16 in total

1.  Valproic acid-associated encephalopathy.

Authors:  G L Jones; F Matsuo; J R Baringer; W H Reichert
Journal:  West J Med       Date:  1990-08

2.  Valproate-induced hyperammonemic encephalopathy: a case report.

Authors:  Vikas Mangewala; Sajjad Sarwar; Ryan Rosenberger; Theodor Rais; Michele Knox
Journal:  Innov Clin Neurosci       Date:  2013-05

3.  Hyperaminoacidemia in epileptic children treated with valproic acid.

Authors:  M Castro-Gago; E Rodrigo-Saez; I Novo-Rodriguez; M F Camiña; S Rodriguez-Segade
Journal:  Childs Nerv Syst       Date:  1990-12       Impact factor: 1.475

4.  N-carbamylglutamate augments ureagenesis and reduces ammonia and glutamine in propionic acidemia.

Authors:  Nicholas Ah Mew; Robert McCarter; Yevgeny Daikhin; Itzhak Nissim; Marc Yudkoff; Mendel Tuchman
Journal:  Pediatrics       Date:  2010-06-21       Impact factor: 7.124

Review 5.  N-acetylglutamate synthase: structure, function and defects.

Authors:  Ljubica Caldovic; Nicholas Ah Mew; Dashuang Shi; Hiroki Morizono; Marc Yudkoff; Mendel Tuchman
Journal:  Mol Genet Metab       Date:  2010-02-26       Impact factor: 4.797

Review 6.  Valproate-associated hepatotoxicity and its biochemical mechanisms.

Authors:  M J Eadie; W D Hooper; R G Dickinson
Journal:  Med Toxicol Adverse Drug Exp       Date:  1988 Mar-Apr

7.  Increased sensitivity to the anticonvulsant effect of valproate in aging BN/BiRij rats.

Authors:  A M Stijnen; S Hovinga; M W Langemeijer; A Hoogerkamp; C F van Bezooijen; M Danhof
Journal:  Pharm Res       Date:  1993-07       Impact factor: 4.200

Review 8.  N-acetylglutamate and its changing role through evolution.

Authors:  Ljubica Caldovic; Mendel Tuchman
Journal:  Biochem J       Date:  2003-06-01       Impact factor: 3.857

Review 9.  Valproate hepatotoxicity syndrome: hypotheses of pathogenesis.

Authors:  J R Stephens; R H Levy
Journal:  Pharm Weekbl Sci       Date:  1992-06-19

10.  Valproic Acid-induced hyperammonemia in the elderly: a review of the literature.

Authors:  Vikrant Mittal; Sunanda Muralee; Rajesh R Tampi
Journal:  Case Rep Med       Date:  2009-08-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.